We will discuss:
- How the value of preclinical data lies in how it is curated, interpreted and applied in decision-making
- Why transparency, interpretability and reproducibility are essential for predictive technologies to be accepted and trusted
- Ways data-driven technologies can effectively integrate with regulatory workflows such as ICH S1B, ICH M7 and emerging frameworks such as ICH Q3E
- How these data-driven technologies support toxicity profiling, lead compound selection and evaluation of preclinical predictivity for clinical outcomes
Speakers:
- Frances Hall, PhD, Scientific Application Director, Instem (Presenter)
- Candice Johnson, PhD, Product Manager, Instem (Presenter)
- Brenda Finney, PhD, Director of Product – In Silico & Data Insights, Instem (Q&A Panelist)
- Kevin Cross, PhD, Director of In Silico Science, Instem (Q&A Panelist)
